Cheap TB drug to flood market as bedaquiline patent expires

A key tuberculosis medication is losing patent protection, potentially slashing costs for drug-resistant TB treatment in developing countries. The move could reshape pricing for infectious disease treatments across low- and middle-income nations, where drug affordability remains a critical barrier to controlling global health threats.

Originaltitel: End of the Bedaquiline patent - a crucial development for moving forward affordable drugs, diagnostics, and vaccines for infectious diseases in low- and middle-income countries